Philippe Villain-Guillot, Nosopharm, highlights how the company is countering multi-drug antimicrobial resistance and explains how partnering with the company is an opportunity for the pharmaceutical businesses to grow their antibacterial pipeline
Philippe Villain-Guillot, Nosopharm, highlights how the company is countering multi-drug antimicrobial resistance and explains how partnering with the company is an opportunity for the pharmaceutical businesses to grow their antibacterial pipeline
Philippe Villain-Guillot, Nosopharm
The week's biggest stories from this industry, direct to your inbox.
